

Drug repurposing in oncology

Lydie Meheus
Managing Director Anticancer Fund

Goed Gebruik Geneesmiddelen, Amsterdam, 19 April 2018

Drug repurposing landscape



The Scientist » January 2017 Issue » Features

Repurposing Existing Drugs for New Indications

An entire industry has sprung up around resurrecting failed drugs and recycling existing compounds for novel indications.

By Anna Azvolinsky | January 1, 2017

Due to this **lack of monetary incentive**, “generic drugs found to work for a new disease are in a state of purgatory,” says Wegner.

Indeed, no generic drug has ever been approved for a new indication by a manufacturer without modification of the drug’s delivery or its dose, which would provide renewed patent protection.

Someone needs to step up to help move preliminary findings about these cheap and available drugs into the clinic where they can help patients, Wegner adds.

“This is where foundations, advocacy groups, and the NIH can play a huge role.”

Craig Wegner, Astra Zeneca

Support of independent clinical trials

Focus area

- Drug repurposing
- Combination therapies (7)
- Less common and rare cancers (3)
- Preventing tumour recurrence (2)

Cancer types

- Brain cancer (2)
- Blood cancer (1)
- Bone cancer (1)
- Breast cancer (1)
- Digestive cancer (1)
- Gynaecological cancer (1)
- Lung cancer (1)
- Melanoma (1)
- Paediatric cancer (1)
- Solid tumour (1)

Status


- Recruiting

Project phase

- 1 (2)
- 1b (1)
- 2 (4)
- 3 (2)

<p>AML-VIVA</p> <p>Treating leukaemia patients with chemotherapy and 2 repurposed drugs</p> <p>Status: Recruiting Cancer types: Blood cancer Trial phase: 2</p> <p>View project</p>	<p>FLUVABREX</p> <p>Anti-inflammatory and cholesterol inhibitor as repurposed drugs for children's optic nerve cancer</p> <p>Status: Recruiting Cancer types: Paediatric cancer, Brain cancer Trial phase: 1</p> <p>View project</p>	<p>MODULUNG</p> <p>Combination of 3 repurposed drugs after chemotherapy failure in lung cancer</p> <p>Status: Recruiting Cancer types: Lung cancer Trial phase: 2</p> <p>View project</p>	<p>ASPIRIN</p> <p>Aspirin for recurrence and survival in colon cancer</p> <p>Status: Recruiting Cancer types: Digestive cancer Trial phase: 3</p> <p>View project</p>	<p>CUSP9v3</p> <p>Combination of 9 repurposed drugs with low-dose chemotherapy in brain cancer</p> <p>Status: Recruiting Cancer types: Brain cancer Trial phase: 1</p> <p>View project</p>	<p>METZOLIMOS</p> <p>Advanced bone cancer treatment with a combination of chemotherapy and immunosuppressants</p> <p>Status: Recruiting Cancer types: Solid tumour, Bone cancer Trial phase: 1b</p> <p>View project</p>
<p>PIONEER</p> <p>Pre-operative hormone treatment for ER+ breast cancer patients</p> <p>Status: Recruiting Cancer types: Breast cancer Trial phase: 2</p> <p>View project</p>	<p>PRIMMO</p> <p>Immunotherapy, radiation and an immune modulatory combination in cervical and uterine cancer</p> <p>Status: Recruiting Cancer types: Gynaecological cancer Trial phase: 2</p> <p>View project</p>	<p>VIDME</p> <p>Vitamin D treatment for melanoma</p> <p>Status: Recruiting Cancer types: Melanoma Trial phase: 3</p> <p>View project</p>	<p>Trial portfolio of the ACF</p> <p>Drug repurposing focus</p>		

If no change






ACF invited by STAMP (European Commission)

How can regulatory pathways be adapted so that adding a new indication to an existing label can be:

1. Requested by a non-commercial party performing independent research
2. Assessed by EMA and/or joint clinical HTA assessment
3. Implemented by the producers (MAHs) at a low/reasonable cost

Create awareness in the European Parliament



More can be done if we exclude “profit” as a driver in cancer research and focus on patient benefits instead.

Rol van ZonMw?

3.5 Mogelijkheden voor verbetering


Do-it-yourself medicine: de oplossing is om deze experimenten (medicijncoctail in GBM) in de reguliere zorgverlening te brengen in de vorm van klinische trials en te begeleiden en ondersteunen.

4.7 Nagaan waar niet-commerciële geneesmiddelenontwikkeling wenselijk is

Drug rediscovery

**Ontwikkeling nieuwe
geneesmiddelen**

Beter, sneller, goedkoper



raad voor **V**olksgezondheid en
Samenleving

The Anticancer Fund

Independent non-profit organisation dedicated to expanding the range of treatment options available to cancer patients, regardless of commercial value.

science and evidence-based medicine at the service of patients and our society

We believe priority should be given to pragmatism and realising tangible impact with preferably short term results.

We are driven by the **unmet needs** of many cancer patients and the **untapped potential of potential pathways** leading to additional treatment options.



Brussels based.
Internationally active

Research institute &
knowledge platform

Privately funded, no
commercial
shareholders or
interest groups

Strategic and
financial activation
of independent
clinical trials

Disclosure belangen spreker

(potentiële) belangenverstrengeling	Geen
Voor bijeenkomst mogelijk relevante relaties met bedrijven	Bedrijfsnamen
<ul style="list-style-type: none">• Sponsoring of onderzoeksgeld• Honorarium of andere (financiële) vergoeding• Aandeelhouder• Andere relatie, namelijk ...	<ul style="list-style-type: none">••••